Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Tennessee: below-average open trial sites
1,176 of 3,520 in-state trials are recruiting (33%); below the 37% national average by 4 percentage points, with Phase 2 weight.
According to ClinicalTrials.gov-derived indexes, Tennessee sits in the upper half of US states by in-state trial count (#19 of 52 states by registered in-state trial count).
Tennessee: 3,520 US clinical trials with in-state sites, 1,176 recruiting.
Tennessee has 3,520 registered US clinical trials with a study site in-state, 1,176 of them currently recruiting (below the 37% national average by 4 percentage points). 491 of these trials are in Phase 3 (late-stage) and 766 in Phase 2. The most frequently studied condition in Tennessee is Breast Cancer, with 104 linked trials.
Mid-pack research density
Tennessee sits in the upper half of the state corpus, so volume is meaningful but not hub-scale. Use condition and sponsor rollups below to see what drives the in-state mix.
Below-average open, early-phase tilt
Tennessee still shows 1,176 recruiting of 3,520 in-state trials (33% open), but below the 37% national average by 4 percentage points, so archived statuses weigh heavier than the national baseline.
- 33%
- open (below national share)
- 1,176
- still recruiting despite cool share
- 766
- Phase 2 rows in this footprint
- 104
- top: Breast Cancer
Recruiting share is below the 37% national average by 4 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Tennessee vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
3,520 Top 37% more indexed trials than 63% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Tennessee on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Tennessee open-enrollment share sits below the national baseline.
1,176 of 3,520 in-state trials (33.4%) are recruiting, against 37% nationally (-3.6 percentage points). Counts include every study with at least one recorded site in the state.
-
Nashville dominates Tennessee's trial geography.
Nashville lists 2,216 of 3,520 in-state trials (63%) across 600 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in Tennessee.
104 of 3,520 in-state trials (3%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
Tennessee sponsorship is fragmented across many organizations.
Vanderbilt University Medical Center appears on 285 of 3,520 in-state trials (8.1%). Sponsor identity is as filed on ClinicalTrials.gov.
-
1,514 Tennessee trials carry a completed status.
1,514 of 3,520 (43%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 1,514 |
| Recruiting | 1,176 |
| Active | 830 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 1 | 916 |
| Phase 2 | 766 |
| NA | 695 |
| Phase 3 | 491 |
| Phase 4 | 130 |
| Early Phase 1 | 28 |
Top Conditions
Top Sponsors
Where trials run in Tennessee
Nashville carries 2,216 of Tennessee's 3,520 indexed trials (63%) across 600 named sites, ahead of Memphis at 729. 8 cities clear five listed trials, together naming 1,263 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Nashville | 2,216 | 600 |
| Memphis | 729 | 272 |
| Knoxville | 311 | 173 |
| Chattanooga | 165 | 92 |
| Germantown | 106 | 59 |
| Jackson | 39 | 26 |
| Kingsport | 33 | 21 |
| Franklin | 27 | 20 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Trial size small
Tennessee's in-state trials target 559 patients on average (p6 by trial size among 52 states with enrollment data), smaller studies than most states.
Tennessee: in-state trial volume sits mid-pack
Geography is concentrated: Nashville alone accounts for 63% of Tennessee's indexed trials (2,216 of 3,520), with Memphis a distant second at 729.
Phase mix: 491 Phase 3 vs 766 Phase 2 (early-phase heavy).
Top condition: Breast Cancer (104 trials); top sponsor Vanderbilt University Medical Center (285).
mid-volume · mid-open figures (3,520 trials · 33% open) describe registry geography under the trial size small read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Tennessee on in-state trial volume
Cross-state peers under the trial size small read (mid-volume · mid-open), not the same-state browse list.
Similar mid-volume peers (± open share)
- Connecticut · 3,531 trials · 32% recruiting
- Indiana · 3,113 trials · 29% recruiting
- Missouri · 4,116 trials · 33% recruiting
- Alabama · 4,168 trials · 29% recruiting
- Washington · 2,795 trials · 33% recruiting
Similar mid-open peers (± trial volume)
- Illinois · 33% recruiting · 6,854 trials
- Delaware · 33% recruiting · 652 trials
- New Jersey · 34% recruiting · 3,402 trials
- Maryland · 34% recruiting · 6,441 trials
- Florida · 33% recruiting · 10,986 trials